Please login to the form below

Not currently logged in
Email:
Password:

Incivo

This page shows the latest Incivo news and features for those working in and with pharma, biotech and healthcare.

2015's 'premium' prices dissuaded J&J from acquisitions, says Gorsky

2015's 'premium' prices dissuaded J&J from acquisitions, says Gorsky

to $8.1bn despite heavy competition to hepatitis C therapies Olysio (simeprevir) and Incivo (telaprevir) from Gilead and AbbVie.

Latest news

More from news
Approximately 1 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    172. Vertex / Janssen. Royalty sale. Sale of product royalty rights relating to INCIVO (telaprevir) to Janssen Pharmaceutica.

  • Drug pricing in Ireland Drug pricing in Ireland

    It said that up to 10 new medicines that had proved cost effective through HTA – including Brilique, Gileyna, Sycrest, Incivo and Victrelis – were still not being reimbursed.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics